{"url_path":"/sec/stro/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-224065-index.html","accession_number":"0001193125-26-224065","cik":"0001382101","ticker":"STRO","issuer_name":"SUTRO BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-224065-index.html","primary_entity_key":"0001382101","primary_entity_name":"SUTRO BIOPHARMA, INC."},"word_count":133,"has_tables":true,"body_markdown":"Item 2.02. Results of Operations and Financial Condition.\n\nOn May 14, 2026, Sutro Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this report.\n\nThe information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such a filing."}